Auro Laboratories Ltd Fair Value
AUROLAB · Healthcare · Current price ₹260.4
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹68 | 8% ROE fading to 14% over ~3 yrs, on ₹74 book |
| Relative P/E | ₹386 | EPS × 30.9 peer-median P/E |
| Graham floor | ₹145 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Auro Laboratories Ltd undervalued?
DocStoX estimates the fair value of Auro Laboratories Ltd at ₹169 per share, versus the current market price of ₹260. That puts the stock about -34.9% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹68), Relative P/E (₹386), Graham floor (₹145). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹68 (bear) to ₹169 (base) to ₹386 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Auro Laboratories Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.